OraSure Technologies, Inc. $OSUR Stock Position Lifted by Sei Investments Co.

Sei Investments Co. raised its stake in OraSure Technologies, Inc. (NASDAQ:OSUR) by 126.9% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 417,958 shares of the medical instruments supplier’s stock after buying an additional 233,732 shares during the quarter. Sei Investments Co. owned 0.61% of OraSure Technologies worth $1,254,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in OSUR. Quadrature Capital Ltd acquired a new stake in shares of OraSure Technologies during the 4th quarter valued at $28,000. Prudential Financial Inc. acquired a new position in shares of OraSure Technologies in the second quarter worth $31,000. Diversify Wealth Management LLC acquired a new position in shares of OraSure Technologies in the first quarter worth $36,000. Amundi acquired a new position in shares of OraSure Technologies in the first quarter worth $47,000. Finally, SG Americas Securities LLC raised its holdings in shares of OraSure Technologies by 77.7% during the fourth quarter. SG Americas Securities LLC now owns 19,748 shares of the medical instruments supplier’s stock worth $48,000 after acquiring an additional 8,632 shares in the last quarter. Hedge funds and other institutional investors own 93.50% of the company’s stock.

Insider Buying and Selling at OraSure Technologies

In related news, Director Steven Kyle Boyd acquired 25,000 shares of the business’s stock in a transaction that occurred on Thursday, May 14th. The shares were acquired at an average cost of $2.99 per share, with a total value of $74,750.00. Following the purchase, the director owned 113,462 shares of the company’s stock, valued at approximately $339,251.38. The trade was a 28.26% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 4.70% of the company’s stock.

Analyst Ratings Changes

OSUR has been the subject of a number of research reports. Wall Street Zen raised OraSure Technologies from a “sell” rating to a “hold” rating in a research report on Monday. Weiss Ratings raised OraSure Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, June 4th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Reduce” and an average price target of $3.00.

OraSure Technologies Price Performance

NASDAQ OSUR opened at $3.88 on Wednesday. OraSure Technologies, Inc. has a fifty-two week low of $2.08 and a fifty-two week high of $4.58. The stock’s 50-day moving average is $4.16 and its two-hundred day moving average is $3.45. The firm has a market cap of $267.13 million, a P/E ratio of -5.62 and a beta of 1.00.

About OraSure Technologies

OraSure Technologies, Inc is a Bethlehem, Pennsylvania–based diagnostic and medical device company specializing in the development, manufacture and commercialization of point-of-care and self-testing products. Founded in 1988, OraSure has built a portfolio of oral fluid and other non-invasive specimen collection technologies that support the detection of infectious diseases, drugs of abuse, and health and wellness biomarkers.

The company’s flagship product, the OraQuick® rapid HIV test, was the first Food and Drug Administration–approved over-the-counter oral fluid test for the detection of HIV-1/2 antibodies.